Practice-changing research shows that a combination of androgen deprivation therapy — a commonly used hormone injection — plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years.
New combined therapy helps extend lives of men with prostate cancer
